DCPX.F Stock Overview

A biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. More details

DCPX.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($13M)

Earnings have declined by 37.2% per year over past 5 years

Shares are highly illiquid

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

DanCann Pharma A/S Competitors

SciSparc

NasdaqCM:SPRC

US$2.9m

InMed Pharmaceuticals

NasdaqCM:INM

US$3.2m

Medicine Man Technologies

OTCPK:SHWZ

US$1.6m

Valeo Pharma

OTCPK:VPHI.F

US$4.6m

Price History & Performance

Summary of share price highs, lows and changes for Dancann Pharma
Historical stock prices
Current Share Price	DKK 0.01
52 Week High	DKK 0.01
52 Week Low	DKK 0.01
Beta	1.94
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	DCPX.F	US Pharmaceuticals	US Market
7D	0%	0.2%	-0.5%
1Y	n/a	2.0%	23.2%

Return vs Industry: Insufficient data to determine how DCPX.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how DCPX.F performed against the US Market.

Price Volatility

Is DCPX.F's price volatile compared to industry and market?
DCPX.F volatility
DCPX.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: DCPX.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DCPX.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	10	Jeppe Rasmussen	www.dancann.com

Dancann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in various disease areas. The company produces and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. Dancann Pharma A/S was incorporated in 2018 and is based in Ansager, Denmark.

DanCann Pharma A/S Fundamentals Summary

How do Dancann Pharma's earnings and revenue compare to its market cap?
DCPX.F fundamental statistics
Market cap	US$1.83m
Earnings (TTM)	-US$1.78m
Revenue (TTM)	US$1.03m

1.8x

P/S Ratio

-1.0x

P/E Ratio

Is DCPX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DCPX.F income statement (TTM)
Revenue	DKK 7.15m
Cost of Revenue	DKK 10.61m
Gross Profit	-DKK 3.46m
Other Expenses	DKK 8.88m
Earnings	-DKK 12.34m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.074
Gross Margin	-48.32%
Net Profit Margin	-172.53%
Debt/Equity Ratio	0%

How did DCPX.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/04/02 22:24
End of Day Share Price	2024/01/04 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DanCann Pharma A/S is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Markus Augustsson	Carlsquare AB
Jonatan Andersson	Carlsquare AB
Fredrik Nilsson	Carlsquare AB